BioTE Medical, LLC entered into a definitive agreement to acquire Asteria Health for $9 million on January 17, 2024. The consideration consists of $8.5 million in cash and $0.5 million based on certain production metrics achieved by April 1, 2024. Biote will fund the transaction with cash from its balance sheet.

Asteria Helath team is joining Biote. The acquisition is subject to customary closing conditions, with closing anticipated to occur in the first quarter of 2024. The Company expects to close in early 2024.

Truist Securities, Inc. acted as financial advisor to biote Corp.